Herpes Simplex Virus-2 is a sexually transmitted viral infection, which often produces painful sores, usually in the genital area. Once infected, an individual may carry the virus and be subject to recurrent bouts of infection. Some estimate that as many as 20 percent of the adult population in the United States has been exposed to the virus.
A recent study of men co-infected with herpes simplex virus type 2 (HSV-2) and HIV revealed that drugs used to suppress HSV decrease the levels of HIV in the blood and rectal secretions, which may make patients less likely to transmit the virus.
What are the cancer drugs of tomorrow and how will they be developed? At the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, researchers will present some answers to these and other pressing questions regarding emerging cancer therapeutics.
A team of University of Kentucky researchers has identified the roles that herpes simplex virus type 1 (HSV-1) proteins play during the invasion of cells and the formation of skin lesions known as cold sores and fever blisters.
Long-term anti-herpes treatment of women infected with both HIV and HSV2, the virus that causes genital herpes, may reduce the proportion of women with detectable HIV virus in their genital secretions according to the results of a trial in Tanzania presented the International AIDS Society Conference in Sydney.
A genetically engineered herpes simplex virus, primarily known for causing cold sores, may help keep arteries "free-flowing" in the weeks following angioplasty or stent placement for patients, according to research published early in the online edition of PNAS (Proceedings of the National Academy of Sciences of the United States of America).
Scientists have developed a virus specifically designed to target cancer tissue while not affecting normal healthy tissue.
A virus that has been specifically designed by scientists to be safe to normal tissue but deadly to cancer is showing early promise in a preliminary study, researchers said at the ESMO Conference Lugano (ECLU), Switzerland.
Rats with erectile dysfunction, or ED, that were injected with a gene therapy vector containing either of two nerve growth factors were able to regain normal function after four weeks, according to a study conducted by University of Pittsburgh School of Medicine researchers.
Researchers from the University of Pittsburgh School of Medicine report that they have successfully used gene therapy to block the pain response in an animal model of neuropathic pain, a type of chronic pain in people for which there are few effective treatments.
By adulthood, most people have suffered at least one bout of painful cold sores brought on by the Herpes simplex virus 1, also known as HSV-1.
They say this strategy could offer a novel way of treating many cancers associated with Epstein-Barr, including at least four different types of lymphoma and nasopharyngeal and gastric cancers.
Treatment of genital herpes could slow the progression of HIV in people living with both viruses, according to a study published in the Feb. 22 issue of the New England Journal of Medicine.
Experts call for HSV control measures, including vaccine, to rank high on international HIV prevention and research agenda as exciting trial findings are published.
A researcher at Montana State University has called for an innovative, new approach in developing a vaccine against genital herpes.
For the first time, researchers have identified a peptide that can spur cargo transport in nerve cells, a discovery that could help scientists better understand nerve cell function and test possible therapies for neurodegenerative diseases.
Researchers here have discovered how a specific chemotherapy drug helps a cancer-killing virus. The virus is being tested in animals for the treatment of incurable human brain tumors.
The prevalence of herpes in the U.S. is declining, according to a study published in the Aug. 23 edition of the Journal of the American Medical Association, Reuters reports (Reuters, 8/22).
The findings of a WHO/UNAIDS consultation presented at the XVI International AIDS Conference confirm that caring for sexually transmitted infections (STIs) at the right stage of an epidemic and targeting them at key population groups can reduce HIV transmission.
SARS coronavirus protein called "nsp1" causes the breakdown of biochemical messages that normally prompt the production of a protein critical to defending the body against viruses.
Giving an anti-viral drug to pregnant women who have a history of genital herpes significantly lowers the rate of Caesarean sections needed to protect the infant from becoming infected with the virus, researchers at UT Southwestern Medical Center have found.